GPC Biotech Announces Data from Several Satraplatin Clinical Trials to be Presented at ASCO Annual Meeting
28 Mai 2008 - 9:07AM
Business Wire
GPC Biotech AG (Frankfurt Stock Exchange: GPC; NASDAQ: GPCB) today
announced that data from several satraplatin clinical trials will
be presented at the 44th American Society of Clinical Oncology
(ASCO) Annual Meeting taking place in Chicago, Ill., May 30-June 3,
2008. Details are as follows: �Satraplatin in patients with
advanced hormone-refractory prostate cancer: Overall survival
results from the phase III satraplatin and prednisone against
refractory cancer (SPARC) trial,� (Abstract #5003), Presenter: A.
Oliver Sartor, MD, oral presentation in Chemotherapy for Metastatic
Prostate Cancer: New Taxane Combinations and Post-Taxane Options
clinical science symposium, W375e, Sunday, June 1, 11:30 AM � 1:00
PM �Phase I study of satraplatin and docetaxel in solid
malignancies,� (Abstract #2570), Presenter: Ticiana B Leal, MD,
Poster #13B, Developmental Therapeutics: Cytotoxic Chemotherapy
general poster session, S Hall A1, Sunday, June 1, 2:00 PM � 6:00PM
�Phase I study of the oral platinum agent satraplatin in sequential
combination with capecitabine in patients with advanced solid
tumours,� (Abstract #2560), Presenter: Cristiana Sessa, MD, Poster
#11 H, Developmental Therapeutics: Cytotoxic Chemotherapy general
poster session, S Hall A1, Sunday, June 1, 2:00 PM � 6:00PM �Phase
I study of oral platinum with concurrent radiation therapy in non
small cell lung cancer,� (Abstract #7560) Presenter: Hak Choy, MD.,
Poster #35B, Lung Cancer � Local-Regional and Adjuvant Therapy
general poster session, S Hall A1, Sunday, June 1, 2:00 PM � 6:00PM
The abstracts are available online at www.asco.org. About GPC
Biotech GPC Biotech AG is a publicly traded biopharmaceutical
company focused on anticancer drugs. GPC Biotech's lead product
candidate is satraplatin, an oral platinum compound. The Company
has various anti-cancer programs in research and development that
leverage its expertise in kinase inhibitors. GPC Biotech AG is
headquartered in Martinsried/Munich (Germany) and has a wholly
owned U.S. subsidiary in Princeton, New Jersey. For additional
information, please visit GPC Biotech's Web site at
www.gpc-biotech.com. This press release contains forward-looking
statements, which express the current beliefs and expectations of
the management of GPC Biotech. Such statements are based on current
expectations and are subject to risks and uncertainties, many of
which are beyond our control, that could cause future results,
performance or achievements to differ significantly from the
results, performance or achievements expressed or implied by such
forward-looking statements. Actual results could differ materially
depending on a number of factors, and we caution investors not to
place undue reliance on the forward-looking statements contained in
this press release. We direct you to GPC Biotech�s Annual Report on
Form 20-F for the fiscal year ended December 31, 2006 and other
reports filed with the U.S. Securities and Exchange Commission for
additional details on the important factors that may affect the
future results, performance and achievements of GPC Biotech.
Forward-looking statements speak only as of the date on which they
are made and GPC Biotech undertakes no obligation to update these
forward-looking statements, even if new information becomes
available in the future.
Gpc Biotech AG ADS (MM) (NASDAQ:GPCB)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Gpc Biotech AG ADS (MM) (NASDAQ:GPCB)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024